Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 14Gynecologic 12Thoracic 4Sarcoma 4Genitourinary 3Gastrointestinal 2Tumor-Agnostic 1Head & Neck 1CNS 1

Conditions

Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1

Interventions

Oxaliplatin 1004Fluorouracil 800Capecitabine 764Gemcitabine 650Leucovorin 559Irinotecan 537Bevacizumab 513Radiotherapy 460Cisplatin 440Drug Therapy 298Cetuximab 280Surgical Procedures, Operative 229Paclitaxel 228S 1 (combination) 217pembrolizumab 205Docetaxel 199130-nm albumin-bound paclitaxel 196Nivolumab 193sintilimab 191Radiosurgery 190lenvatinib 180Folfox protocol 179Sorafenib 178Albumin-Bound Paclitaxel 173apatinib 170tislelizumab 161camrelizumab 160Neoadjuvant Therapy 158Blood Specimen Collection 154durvalumab 148

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × fluzoparib × Gastrointestinal × Clear all
NCT06516445 2024-07-24

SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC

Huazhong University of Science and Technology

Phase 2 Recruiting
33 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06055166 2023-09-26

A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors

Chongqing University Cancer Hospital

Phase 2 Unknown
120 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡